Medicare GLP-1 Bridge: Who Qualifies for $50 Wegovy, Zepbound, or Foundayo

Since July 1, 2026, a temporary Medicare program has covered certain GLP-1 medications for weight management for a $50 copay. Here is who qualifies, which drugs are covered, what it costs, and how to get started.

← Back to all articles

Quick answer

The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 and covers Wegovy (injection or tablet), the Zepbound KwikPen, and Foundayo for weight management.

Eligible people pay a $50 copay for a one-month supply. It does not count toward the Part D deductible or out-of-pocket limit, and Extra Help cannot lower it.

You need Medicare drug coverage, must be 18 or older, and must meet a BMI-based criterion: a BMI of 35 or higher, or a lower BMI with certain health conditions.

People with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease are not eligible for the Bridge, though their Part D plan may cover GLP-1s for those conditions.

What is the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge is a short-term demonstration run by the Centers for Medicare & Medicaid Services (CMS). It gives eligible people with Medicare drug coverage access to certain GLP-1 medications for weight management for a $50 copay, from July 1, 2026 through December 31, 2027.

It works outside the normal Part D benefit. Instead of your Part D plan, CMS uses a single central processor to handle prior authorization, claims, and payment to pharmacies. CMS says it is using the program to collect data ahead of a possible longer-term Medicare model called BALANCE, which will not launch in 2027.

Who qualifies for the Medicare GLP-1 Bridge?

You must have Medicare drug coverage. That includes a standalone Part D plan, a Medicare Advantage plan with drug coverage, a Special Needs Plan, an employer group plan, or the LI NET program. You must also be 18 or older and meet one of these criteria when you start GLP-1 therapy:

Your BMIYou also need
35 or higherNo other condition
30 to 34.9At least one of: heart failure with preserved ejection fraction (diastolic heart failure), uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher
27 to 29.9At least one of: prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms

If you already take a GLP-1 and your BMI has gone down, the BMI from when you started GLP-1 therapy is the one that counts. KFF estimates that nearly four million Medicare beneficiaries met the Bridge eligibility criteria in 2023.

Who is not eligible?

You cannot use the Bridge if:

  • You already get GLP-1 drugs covered through your Part D plan.
  • You have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Your Part D plan may still cover GLP-1s for these conditions under its usual rules.

The Bridge is only for weight management.

Which medications are covered?

The Bridge covers three FDA-approved GLP-1 medications for weight management:

  • Wegovy (semaglutide), as the weekly injection or the daily tablet
  • Zepbound (tirzepatide), KwikPen only. Zepbound single-dose vials and single-dose pens are not covered.
  • Foundayo (orforglipron), a daily tablet

Compounded semaglutide and tirzepatide are not covered.

How much does it cost?

You pay a $50 copayment at the pharmacy for a one-month supply, which is 28 or 30 days depending on the drug. The copay is the same at every dose. A few rules to know:

  • The $50 does not count toward your Part D deductible or your annual out-of-pocket limit.
  • Extra Help (the Part D Low-Income Subsidy) cannot lower it.
  • You cannot spread it across months with the Medicare Prescription Payment Plan.
  • It does not appear on your Part D Explanation of Benefits or Medicare Summary Notice.

For comparison, the same medications cost $149 to $449 a month through the manufacturers' self-pay programs as of November 20, 2026, depending on the medication and dose. See the GLP-1 cost comparison for prices by dose.

How do you get started?

  1. Check whether you qualify with the questionnaire at Medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227). TTY users can call 1-877-486-2048.
  2. Talk with your doctor or another health care provider about whether a GLP-1 is right for you.
  3. Your provider sends a prescription for a covered drug to your pharmacy. When asked, your provider completes a prior authorization and certifies that you are using the drug as part of a diet and exercise program.
  4. The pharmacy may ask for your Medicare Number or the last 4 digits of your Social Security Number.
  5. You get a letter confirming that your drug is covered under the GLP-1 Bridge.

The pharmacy's first claim is expected to be denied. That denial is what triggers the prior authorization request to your provider, usually within 24 to 72 hours. Once approved, the authorization covers refills and dose changes through December 31, 2027, unless you switch to a different GLP-1.

What happens after December 31, 2027?

The Bridge is temporary. CMS extended it through December 31, 2027 to collect data ahead of a possible longer-term model called BALANCE, and has said BALANCE will not launch in 2027. CMS has not said what will replace the Bridge after 2027.

What if you don't qualify?

You may still have options:

  • Your Part D plan may cover a GLP-1 for type 2 diabetes, sleep apnea, or fatty liver disease under its own rules.
  • Manufacturer self-pay programs sell Wegovy, Zepbound, and Foundayo directly; prices start at $149 a month for the lowest doses of the Wegovy pill and Foundayo.
  • Cash-pay telehealth services, including Ondra Health, offer compounded semaglutide and tirzepatide. Medicare does not cover them, and they are not FDA-approved.

Ondra Health does not accept Medicare or insurance. If you qualify for the Bridge, it is likely to cost less than any cash-pay option.

Frequently asked questions

How much does Wegovy cost with Medicare?

Through the Medicare GLP-1 Bridge, eligible people with Medicare drug coverage pay a $50 copay for a one-month supply of Wegovy (injection or tablet), the Zepbound KwikPen, or Foundayo, from July 1, 2026 through December 31, 2027. The copay does not count toward the Part D deductible or out-of-pocket limit.

Does Medicare cover Zepbound for weight loss?

Yes, through the Medicare GLP-1 Bridge, but only the Zepbound KwikPen. Zepbound single-dose vials and single-dose pens are not covered. You must meet the eligibility criteria and get prior authorization.

What BMI do you need for the Medicare GLP-1 Bridge?

A BMI of 35 or higher qualifies on its own. A BMI of 30 to 34.9 qualifies with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher. A BMI of 27 to 29.9 qualifies with prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms. Your BMI from when you started GLP-1 therapy is used.

Can Extra Help lower the $50 GLP-1 Bridge copay?

No. Extra Help cannot lower the GLP-1 Bridge copay, and the $50 does not count toward your Part D deductible or annual out-of-pocket limit.

Does the Medicare GLP-1 Bridge cover compounded semaglutide?

No. The Bridge covers only Wegovy, the Zepbound KwikPen, and Foundayo. Compounded semaglutide and tirzepatide are not covered by Medicare and are not FDA-approved.

How long does the Medicare GLP-1 Bridge last?

The Bridge runs from July 1, 2026 through December 31, 2027. Once approved, your prior authorization covers refills and dose changes through December 31, 2027, unless you switch to a different GLP-1.

† This article is for general information and is not medical, legal, or insurance advice. Medicare program details can change; confirm eligibility and costs at Medicare.gov or 1-800-MEDICARE. Ondra Health does not accept Medicare or insurance and is not affiliated with CMS or Medicare. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy®, Zepbound®, or Foundayo™.